Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?

Critical Care

Volumn 15, Issue 5, 2011, Pages

  Sadique, M Zia ^a   Grieve, Richard ^a   Harrison, David A ^b   Cuthbertson, Brian H ^c   Rowan, Kathryn M ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b and London School of Hygiene Tropical Medicine   (United Kingdom)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; ANTIINFECTIVE AGENT; PROTEIN C; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; FEMALE; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; MALE; MEDICAL AUDIT; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEPSIS; SURVIVAL TIME; UNITED KINGDOM; AGED; CASE CONTROL STUDY; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTI-INFECTIVE AGENTS; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; HUMANS; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES; PROTEIN C; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS; SEPSIS; TREATMENT OUTCOME;

EID: 80053375087     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10468     Document Type: Article

References (64)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
2. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995, 274:968-974. 10.1001/jama.274.12.968, 7674528.
3. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003, 31:2332-2338. 10.1097/01.CCM.0000085141.75513.2B, 14501964.
4. Lindenauer PK, Rothberg MB, Nathanson BH, Pekow PS, Steingrub JS. Activated protein C and hospital mortality in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38:1101-1107. 10.1097/CCM.0b013e3181d423b7, 20154607.
5. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004, 30:589-596. 10.1007/s00134-004-2157-0, 14963646.
6. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006, 10:R42. 10.1186/cc4854, 1550902, 16542492.
7. Karlsson S, Varpula M, Ruokonen E, Pettila V, Parviainen I, Ala-Kokko TI, Kolho E, Rintala EM. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 2007, 33:435-443. 10.1007/s00134-006-0504-z, 17225161.
8. Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004, 8:222-226. 10.1186/cc2917, 522859, 15312201.
9. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554. 10.1056/NEJMoa022139, 12700374.
10. Hofhuis JG, Spronk PE, van Stel HF, Schrijvers AJ, Rommes JH, Bakker J. The impact of severe sepsis on health-related quality of life: a long-term follow-up study. Anesth Analg 2008, 107:1957-1964. 10.1213/ane.0b013e318187bbd8, 19020144.
11. Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA. Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life. Crit Care Med 2000, 28:3599-3605. 10.1097/00003246-200011000-00006, 11098960.
12. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332-1341. 10.1056/NEJMoa050935, 16192478.
13. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, . Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS).
14. US Food and Drug Administration FDA clinical review, drotrecogin alfa (activated), [recombinant human activated protein C (rhAPC)], Xigris™. 2002, Washington, DC: US Food and Drug Administration, US Food and Drug Administration., http://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm193970.pdf
15. . Anti-Infective Advisory Committee, US Food and Drug Administration FDA briefing document: Anti-Infective Advisory Committee, drotrecogin alfa (activated), [recombinant human activated protein C (rhAPC)], Xigris™. 2001, Washington, DC: US Food and Drug Administration, Anti-Infective Advisory Committee, US Food and Drug Administration., http://www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_FDAbriefing.pdf
16. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B, . REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369:836-843. 10.1016/S0140-6736(07)60411-5, 17350452, REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study.
17. Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Gardlund B, Marshall JC, Rhodes A. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008, 34:1935-1947. 10.1007/s00134-008-1266-6, 2995439, 18839141.
18. Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003, 31:1-11. 10.1097/00003246-200301000-00001, 12544986.
19. Davies A, Ridley S, Hutton J, Chinn C, Barber B, Angus DC. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Anaesthesia 2005, 60:155-162. 10.1111/j.1365-2044.2004.04068.x, 15644013.
20. Fowler RA, Hill-Popper M, Stasinos J, Petrou C, Sanders GD, Garber AM. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 2003, 18:181-191. discussion 191-184, 10.1016/j.jcrc.2003.08.009, 14595571.
21. Green C, Dinnes J, Takeda AL, Cuthbertson BH. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Int J Technol Assess Health Care 2006, 22:90-100.
22. Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002, 347:993-1000. 10.1056/NEJMsa020969, 12324556.
23. Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 2003, 18:217-227. 10.1016/j.jcrc.2003.10.005, 14691895.
24. Hodder RV, Hall R, Russell JA, Fisher HN, Lee B. Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort. Crit Care 2009, 13:R78. 10.1186/cc7893, 2717441, 19457240.
25. Vincent JL, O'Brien J, Wheeler A, Wittebole X, Garg R, Trzaskoma BL, Sundin DP. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit Care 2006, 10:R74. 10.1186/cc4909, 1550949, 16684364.
26. Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 1999, 15:423-434. 10.2165/00019053-199915050-00001, 10537960.
27. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making?. Health Econ 2006, 15:677-687. 10.1002/hec.1093, 16491461.
28. Sekhon J, Grieve R. A matching method for improving covariate balance in cost-effectiveness analysis. Health Economics 2011,
29. Rowan KM, Welch CA, North E, Harrison DA. Drotrecogin alfa (activated): real-life use and outcomes for the UK. Crit Care 2008, 12:R58. 10.1186/cc6879, 2447613, 18430215.
30. Sadaka F, O'Brien J, Migneron M, Stortz J, Vanston A, Taylor RW. Activated protein C in septic shock: a propensity-matched analysis. Crit Care 2011, 15:R89. 10.1186/cc10089, 21385410.
31. Dhainaut JF. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy. Curr Med Res Opin 2008, 24:1187-1197. 10.1185/030079908X280563, 18348744.
32. Laterre PF, Nelson DR, Macias W, Abraham E, Sashegyi A, Williams MD, Levy M, Levi M, Utterback B, Vincent JL. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety. J Crit Care 2007, 22:142-152. 10.1016/j.jcrc.2006.09.007, 17548026.
33. Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, Beale R. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care 2009, 13:R103. 10.1186/cc7936, 2717475, 19566927.
34. Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. Surgery 2007, 141:548-561. 10.1016/j.surg.2007.02.004, 17431957.
35. Sashegyi A, Trzaskoma BL, Nelson DR, Williams MD, Macias W. International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH. Curr Med Res Opin 2006, 22:1001-1012. 10.1185/030079906X104713, 16709322.
36. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Perez XL, Sirvent JM. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009, 180:861-866. 10.1164/rccm.200812-1912OC, 19696442.
37. National Institute for Health and Clinical Excellence Guide to the methods of technology appraisal. 2008, London: National Institute for Health and Clinical Excellence, National Institute for Health and Clinical Excellence., http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
38. Harrison DA, Brady AR, Rowan K. Case mix, outcome and length of stay for admissions to adult, general critical care units in England, Wales and Northern Ireland: the Intensive Care National Audit & Research Centre Case Mix Programme Database. Crit Care 2004, 8:R99-111. 10.1186/cc2834, 420043, 15025784.
39. DocDat The directory of clinical databases DocDat., http://www.icapp.nhs.uk/docdat/
40. Wright JC, Plenderleith L, Ridley SA. Long-term survival following intensive care: subgroup analysis and comparison with the general population. Anaesthesia 2003, 58:637-642. 10.1046/j.1365-2044.2003.03205.x, 12790812.
41. National Institute for Health and Clinical Excellence Drotrecogin alpha (activated) for severe sepsis. 2004, London: National Institute for Health and Clinical Excellence, National Institute for Health and Clinical Excellence., http://guidance.nice.org.uk/TA84
42. Department of Health NHS reference costs 2009-2010. 2011, London: Department of Health, Department of Health.
43. Curtis L. Unit costs of health & social care 2010. 2010, Canterbury, UK: Personal Social Services Research Unit, University of Kent., http://www.pssru.ac.uk/pdf/uc/uc2010/uc2010.pdf
44. Leventhal H, Colman S. Quality of life: a process view. Psychol Health 1997, 12:753-767.
45. Cuthbertson BH, Roughton S, Jenkinson D, Maclennan G, Vale L. Quality of life in the five years after intensive care: a cohort study. Crit Care 2010, 14:R6. 10.1186/cc8848, 2875518, 20089197.
46. Soares MO, Welton NJ, Harrison DA, Peura P, Shankar HM, Harvey SE, Madan JJ, Ades AE, Palmer SJ, Rowan KM. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and sepsis shock): incorporating a systematic review, meta analysis and value of information analysis. Health Technology Assessment 2011,
47. Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. Health Technol Assess 2005, 9:1-126. iii-iv.
48. Cuthbertson BH, Scott J, Strachan M, Kilonzo M, Vale L. Quality of life before and after intensive care. Anaesthesia 2005, 60:332-339. 10.1111/j.1365-2044.2004.04109.x, 15766335.
49. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. Centre for Health Economics Discussion Paper 1995, 138:1-19.
50. Young JD, Goldfrad C, Rowan K. Development and testing of a hierarchical method to code the reason for admission to intensive care units: the ICNARC Coding Method. Intensive Care National Audit & Research Centre. Br J Anaesth 2001, 87:543-548. 10.1093/bja/87.4.543, 11878722.
51. Buis ML. Using and interpreting restricted cubic splines. 2009, Tübingen, Germany: Institut für Soziologie, Eberhard Karls Universität Tübingen., http://fmwww.bc.edu/repec/dsug2009/buis.pdf
52. Grieve R, Sekhon JS, Hu TW, Bloom JR. Evaluating health care programs by combining cost with quality of life measures: a case study comparing capitation and fee for service. Health Serv Res 2008, 43:1204-1222. 10.1111/j.1475-6773.2008.00834.x, 2517267, 18355261.
53. Gilligan MJ, Sargenti EJ. Do UN interventions cause peace? Using matching to improve causal interference. Quarterly Journal of Political Science 2008, 3:89-122.
54. Gordon SC, Huber GA. The effect of elecoral competitiveness on incumbent behaviour. Quarterly Journal of Political Science 2007, 2:107-138.
55. Heron MC, Wand J. Assessing partisan bias in voting technology: the case of the 2004 New Hamshire recount. Elect Stud 2007, 26:247-261.
56. Imbens GM, Wooldridge JM. Recent developments in the econometrics of program evaluation. Journal of Economic Literature 2009, 47:5-86.
57. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009, 28:3083-3107. 10.1002/sim.3697, 19757444.
58. Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, McNeil BJ. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001, 54:387-398. 10.1016/S0895-4356(00)00321-8, 11297888.
59. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998, 18:S68-80. 10.1177/0272989X9801800209, 9566468.
60. Davison AC, Hinkley DV. Bootstrap Methods and Their Application. 1997, New York: Cambridge University Press.
61. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. Health Econ 2004, 13:405-415. 10.1002/hec.903, 15127421.
62. Eli Lilly and Company Xigris NICE submission: drotrecogin alfa (activated) for severe sepsis. 2003, Basingstoke, UK: Eli Lilly and Company, Eli Lilly and Company.
63. Camporota L, Wyncoll D. Practical aspects of treatment with drotrecogin alfa (activated). Crit Care 2007, 11(Suppl 5):S7. 10.1186/cc6158, 2230611, 18269694.
64. Dhainaut JF, Payet S, Vallet B, Franca LR, Annane D, Bollaert PE, Le Tulzo Y, Runge I, Malledant Y, Guidet B, Le Lay K, Launois R, . PREMISS Study Group Cost-effectiveness of activated protein C in real-life clinical practice. Crit Care 2007, 11:R99. 10.1186/cc6116, 2556742, 17822547, PREMISS Study Group.